Aficamten shows potential to be first FDA-approved treatment for nonobstructive HCM
New data presented at ESC Congress 2026 represent a huge breakthrough for patients with nonobstructive HCM. "For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease," one researcher explained.
New data presented at ESC Congress 2026 represent a huge breakthrough for patients with nonobstructive HCM. "For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease," one researcher explained.
What's Your Reaction?
